Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level

Abstract

Background and PurposeEndomorphins have shown great promise as pharmaceutics for the treatment of pain. We have previously confirmed that novel endomorphin analogues CEMR‐1 and CEMR‐2 behaved as potent μ agonists and displayed potent antinociceptive activities at the supraspinal and peripheral levels. The present study was undertaken to evaluate the antinociceptive properties of CEMR‐1 and CEMR‐2 following intrathecal (i.t.) administration. Furthermore, their antinociceptive tolerance and opioid‐like side effects were also determined.Experimental ApproachThe spinal antinociceptive effects of CEMR‐1 and CEMR‐2 were determined in a series of pain models, including acute radiant heat paw withdrawal test, spared nerve injury‐induced neuropathic pain, complete Freund's adjuvant‐induced inflammatory pain, visceral pain and formalin pain. Antinociceptive tolerance was evaluated in radiant heat paw withdrawal test.Key ResultsSpinal administration of CEMR‐1 and CEMR‐2 produced potent and prolonged antinociceptive effects in acute pain. CEMR‐1 and CEMR‐2 may produce their antinociception through distinct μ receptor subtypes. These two analogues also exhibited significant analgesic activities in neuropathic, inflammatory, visceral and formalin pain at the spinal level. It is noteworthy that CEMR‐1 showed non‐tolerance‐forming analgesic properties, while CEMR‐2 exhibited substantially reduced antinociceptive tolerance. Furthermore, both analogues displayed no or reduced side effects on conditioned place preference response, physical dependence, locomotor activity and gastrointestinal transit.Conclusions and ImplicationsThe present investigation demonstrated that CEMR‐1 and CEMR‐2 displayed potent and long‐lasting antinociception with a favourable side effect profile at the spinal level. Therefore, CEMR‐1 and CEMR‐2 might serve as promising analgesic compounds with minimal opioid‐like side effects.